

PAXLOVID may only be used by healthcare providers to treat mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk5 for progression to severe COVID-19, including hospitalization or death;

Limitations on Authorized Use

• PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19.6

• PAXLOVID is not authorized for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19.

• PAXLOVID is not authorized for use for longer than 5 consecutive days https://www.fda.gov/media/155049/download